<p>根据 Marketbeat 的报道，Gyre Therapeutics, Inc.（NASDAQ:GYRE - 获取免费报告）的股票获得了五家评级机构的平均推荐评级为 “持有”。一位股票研究分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，三位则对该公司给予 “买入” 评级。在过去一年中，更新了对该股票覆盖的分析师的平均十二个月目标价为 17.00 美元。</p>
<p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
<p>GYRE 已经成为几份研究报告的主题。Zacks Research 在 11 月 14 日的报告中将 Gyre Therapeutics 的股票评级从 “强烈卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Gyre Therapeutics 股票的 “卖出（d）” 评级。Wall Street Zen 在 11 月 15 日的研究报告中将 Gyre Therapeutics 的评级从 “持有” 上调至 “买入”。最后，Jefferies Financial Group 在 10 月 10 日的研究报告中开始覆盖 Gyre Therapeutics，并对该股票设定了 “买入” 评级和 16.00 美元的目标价。</p>
<p><strong>阅读我们对 GYRE 的最新股票分析</strong></p>
<h2>Gyre Therapeutics 股票下跌 3.5%</h2>
<p>NASDAQ:GYRE 在周五开盘价为 6.81 美元。Gyre Therapeutics 的十二个月低点为 6.11 美元，十二个月高点为 13.75 美元。该股票的 50 日简单移动平均为 7.60 美元，200 日简单移动平均为 7.65 美元。该公司的市值为 6.5601 亿美元，市盈率为 227.08，贝塔值为 1.99。</p>
<h2>机构投资者对 Gyre Therapeutics 的看法</h2>
<p>几家对冲基金最近增加或减少了在 GYRE 的持股。阿拉斯加州财政部在第三季度购买了 Gyre Therapeutics 的新股份，价值约 38,000 美元。美国银行在第二季度将其在 Gyre Therapeutics 的持股提高了 28.8%。美国银行目前拥有 6,277 股该公司的股票，价值 46,000 美元，此前在该期间又购买了 1,402 股。摩根大通在第二季度将其在 Gyre Therapeutics 的持股增加了 84.6%。摩根大通目前拥有 6,461 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 2,961 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度将其在 Gyre Therapeutics 的持股增加了 77.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有 7,413 股该公司的股票，价值 54,000 美元，此前在该期间又购买了 3,244 股。最后，Lazard Asset Management LLC 在第三季度收购了 Gyre Therapeutics 的新股份，价值约 111,000 美元。目前 23.99% 的股票由机构投资者和对冲基金持有。</p>
<h2>Gyre Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发针对脂质生物学的小分子疗法，以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
<p>Gyre 的临床前管线包括非酒精性脂肪性肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Gyre Therapeutics 更好</li>
<li>崩盘前一个月</li>
<li>请勿删除，立即阅读</li>
<li>前 CIA 官员关于特朗普的信息</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下炸弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1lSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1lSRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Gyre Therapeutics 吗？</h2>
<p>在您考虑 Gyre Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Gyre Therapeutics 并不在名单上。</p>
<p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GYRE

<p>Gyre Therapeutics, Inc.（纳斯达克代码：GYRE）获得了五家分析公司给予的平均评级为 “持有”。评级包括一项卖出、一项持有和三项买入推荐。平均目标价格为 17.00 美元。最近的报告显示，Zacks 将评级从 “强烈卖出” 上调至 “持有”，而 Jefferies 则以 16.00 美元的买入评级开始覆盖该股票。目前该股票的价格为 6.81 美元，12 个月的价格区间为 6.11 美元至 13.75 美元。机构投资者持有该股票的 23.99%，公司专注于开发代谢和神经退行性疾病的治疗方案</p>

<p>Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) have earned an average recommendation of &#34;Hold&#34; from the five ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $17.00.</p>
<div class="lb-trans"><p>根据 Marketbeat 的报道，Gyre Therapeutics, Inc.（NASDAQ:GYRE - 获取免费报告）的股票获得了五家评级机构的平均推荐评级为 “持有”。一位股票研究分析师给予该股票 “卖出” 评级，一位给予 “持有” 评级，三位则对该公司给予 “买入” 评级。在过去一年中，更新了对该股票覆盖的分析师的平均十二个月目标价为 17.00 美元。</p>
</div><p>Get <strong>Gyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
</div><p>GYRE has been the topic of several research reports. Zacks Research raised shares of Gyre Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Gyre Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Gyre Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 15th. Finally, Jefferies Financial Group assumed coverage on Gyre Therapeutics in a research report on Friday, October 10th. They set a &#34;buy&#34; rating and a $16.00 price objective on the stock.</p>
<div class="lb-trans"><p>GYRE 已经成为几份研究报告的主题。Zacks Research 在 11 月 14 日的报告中将 Gyre Therapeutics 的股票评级从 “强烈卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Gyre Therapeutics 股票的 “卖出（d）” 评级。Wall Street Zen 在 11 月 15 日的研究报告中将 Gyre Therapeutics 的评级从 “持有” 上调至 “买入”。最后，Jefferies Financial Group 在 10 月 10 日的研究报告中开始覆盖 Gyre Therapeutics，并对该股票设定了 “买入” 评级和 16.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Stock Analysis on GYRE</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 GYRE 的最新股票分析</strong></p>
</div><h2>Gyre Therapeutics Stock Down 3.5%</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 股票下跌 3.5%</h2>
</div><p>NASDAQ:GYRE opened at $6.81 on Friday. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $13.75. The stock's 50-day simple moving average is $7.60 and its 200 day simple moving average is $7.65. The firm has a market capitalization of $656.01 million, a PE ratio of 227.08 and a beta of 1.99.</p>
<div class="lb-trans"><p>NASDAQ:GYRE 在周五开盘价为 6.81 美元。Gyre Therapeutics 的十二个月低点为 6.11 美元，十二个月高点为 13.75 美元。该股票的 50 日简单移动平均为 7.60 美元，200 日简单移动平均为 7.65 美元。该公司的市值为 6.5601 亿美元，市盈率为 227.08，贝塔值为 1.99。</p>
</div><h2>Institutional Investors Weigh In On Gyre Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Gyre Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in GYRE. State of Alaska Department of Revenue bought a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $38,000. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after buying an additional 1,402 shares during the period. JPMorgan Chase &amp; Co. grew its position in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 6,461 shares of the company's stock valued at $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in Gyre Therapeutics during the 3rd quarter valued at approximately $111,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了在 GYRE 的持股。阿拉斯加州财政部在第三季度购买了 Gyre Therapeutics 的新股份，价值约 38,000 美元。美国银行在第二季度将其在 Gyre Therapeutics 的持股提高了 28.8%。美国银行目前拥有 6,277 股该公司的股票，价值 46,000 美元，此前在该期间又购买了 1,402 股。摩根大通在第二季度将其在 Gyre Therapeutics 的持股增加了 84.6%。摩根大通目前拥有 6,461 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 2,961 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第二季度将其在 Gyre Therapeutics 的持股增加了 77.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前拥有 7,413 股该公司的股票，价值 54,000 美元，此前在该期间又购买了 3,244 股。最后，Lazard Asset Management LLC 在第三季度收购了 Gyre Therapeutics 的新股份，价值约 111,000 美元。目前 23.99% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Gyre Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发针对脂质生物学的小分子疗法，以治疗一系列代谢、炎症和神经退行性疾病。该公司的专有平台结合了脂质组学分析与药物发现工具，以识别选择性调节膜脂质组成并恢复疾病相关细胞中正常蛋白功能的化合物。</p>
</div><p>Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.</p>
<div class="lb-trans"><p>Gyre 的临床前管线包括非酒精性脂肪性肝炎（NASH）、阿尔茨海默病和自身免疫疾病的项目，反映了其在多个治疗领域应用统一脂质靶向方法的战略。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Gyre Therapeutics</li>
<li>A month before the crash</li>
<li>Do not delete, read immediately</li>
<li>A Message From An Ex-CIA Officer About Trump</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Gyre Therapeutics 更好</li>
<li>崩盘前一个月</li>
<li>请勿删除，立即阅读</li>
<li>前 CIA 官员关于特朗普的信息</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下炸弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1lSRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GYRE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Gyre Therapeutics 吗？</h2>
</div><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Gyre Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Gyre Therapeutics 并不在名单上。</p>
</div><p>While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Gyre Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gyre Therapeutics, Inc. (NASDAQ:GYRE) 被分析师给予平均 “持有” 评级